Cargando…

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage

Detalles Bibliográficos
Autores principales:	Nehlmeier, Inga, Kempf, Amy, Arora, Prerna, Cossmann, Anne, Dopfer-Jablonka, Alexandra, Stankov, Metodi V., Schulz, Sebastian R., Jäck, Hans-Martin, Behrens, Georg M. N., Pöhlmann, Stefan, Hoffmann, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165563/ https://www.ncbi.nlm.nih.gov/pubmed/37156807 http://dx.doi.org/10.1038/s41423-023-01030-z

Ejemplares similares

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
por: Hoffmann, Markus, et al.
Publicado: (2023)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
por: Sidarovich, Anzhalika, et al.
Publicado: (2022)

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
por: Arora, Prerna, et al.
Publicado: (2021)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
por: Arora, Prerna, et al.
Publicado: (2022)

No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
por: Arora, Prerna, et al.
Publicado: (2022)

Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India
por: Karyakarte, Rajesh P, et al.
Publicado: (2023)

B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
por: Hoffmann, Markus, et al.
Publicado: (2022)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
por: Jedicke, Nils, et al.
Publicado: (2021)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
por: Hoffmann, Markus, et al.
Publicado: (2022)

Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals
por: Behrens, Georg M. N., et al.
Publicado: (2020)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

Coding-complete genomes of XBB.1.16, XBB.2.3, FL.4 (alias of XBB.1.9.1.4), and XBB.3 of SARS-CoV-2 Omicron isolated from Bangladesh
por: Rahman, Saikt, et al.
Publicado: (2023)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients
por: Brandolini, Martina, et al.
Publicado: (2023)

Health workers’ perception vs medically approved COVID-19 infection risk: the risk communication gap: Ellen Kuhlmann
por: Kuhlmann, E, et al.
Publicado: (2022)

Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins
por: Wrensch, Florian, et al.
Publicado: (2017)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
por: John, Okesanya Olalekan, et al.
Publicado: (2023)

Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant
por: Scarpa, Fabio, et al.
Publicado: (2023)

Distinctive Features of the XBB.1.5 and XBB.1.16 Spike Protein Receptor-Binding Domains and Their Roles in Conformational Changes and Angiotensin-Converting Enzyme 2 Binding
por: Sharma, Tej, et al.
Publicado: (2023)

Healthcare Workers' Perceptions and Medically Approved COVID-19 Infection Risk: Understanding the Mental Health Dimension of the Pandemic. A German Hospital Case Study
por: Kuhlmann, Ellen, et al.
Publicado: (2022)

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
por: Barros-Martins, Joana, et al.
Publicado: (2021)

Omicron spike protein: a clue for viral entry and immune evasion
por: Behrens, G. M. N., et al.
Publicado: (2022)

Competition between variants and SARS-Co-V2 epidemic, from Wuhan to XBB.1.16.: Natural selection?
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iqmq0dhl5mdc2efhfego2u7m9g